StrandPulse 10mg GLP Triple Agonist

StrandPulse Triple is a novel synthetic peptide designed as a triple-agonist (tri-receptor agonist) that simultaneously targets and activates three key hormone receptors:

– GLP-1 receptor (glucagon-like peptide-1)

– GIP receptor (glucose-dependent insulinotropic polypeptide)

– Glucagon receptor (GCG/GCGR)

This multi-receptor mechanism enables researchers to explore synergistic effects on metabolic pathways, including energy expenditure, glucose homeostasis, appetite regulation, and fat metabolism in controlled experimental settings. StrandPulse 10mg GLP Triple Agonist is a 39-amino acid peptide sequence conjugated to a C20 fatty diacid moiety for enhanced stability and prolonged half-life (approximately 6 days in pharmacokinetic studies). Supplied as a white lyophilized powder in a sterile 10mg vial, it offers >98-99% purity (verified via HPLC/third-party testing where applicable). Ideal for studies investigating next-generation metabolic modulation beyond dual-agonist compounds.

– Triple-Agonist Innovation: Balanced activation of GLP-1, GIP, and glucagon receptors for comprehensive metabolic pathway investigation (stronger relative potency at GIP receptor).

– High Purity & Quality**: Sourced for research excellence with third-party verification potential; lyophilized for long shelf-life (stable at -20°C or colder for extended periods).

-Convenient Weekly Dosing Profile** (in models): Half-life supports once-weekly experimental administration.

– Premium Research Focus: Designed for studies on obesity mechanisms, glucose control, energy expenditure, and fat loss pathways—shows promise in preclinical/clinical models for substantial effects.

– Coastal-Brand Appeal: StrandPulse branding ties into Grand Strand Supplements’ premium, science-driven wellness ethos.

– Active Peptide: – 10 mg per vial

– Form: Lyophilized (freeze-dried) powder

– Purity: ≥98-99% (research-grade, batch-specific COA available upon request)

– Excipients/Stabilizers: None added beyond standard lyophilization excipients (e.g., may include trace mannitol or buffers for stability; exact composition varies by synthesis—refer to provided COA)

– Reconstitution Solvent: Not included—typically requires bacteriostatic water or sterile water for injection (research use only)

No additional fillers, preservatives, or human-grade additives are present.

For research and laboratory purposes only.

– Reconstitute the lyophilized powder with an appropriate volume of bacteriostatic water or sterile solvent (e.g., 1-2 mL for desired concentration).

– Store reconstituted solution refrigerated (2-8°C) and use within recommended stability windows (typically days to weeks, depending on protocol).

– Handle under sterile conditions with appropriate lab equipment (syringes, vials, etc.).

– Typical experimental protocols involve subcutaneous or in-vitro administration in model systems to study dose-dependent effects on metabolic parameters.

– Always follow institutional guidelines, GLP standards, and specific study designs. Do not exceed research-appropriate concentrations.

– Research Use Only: Strictly not for human or veterinary use, consumption, injection, or therapeutic application. Not FDA-approved for any medical purpose. Misuse may pose serious health risks.

– Potential Risks in Studies: Known experimental observations include gastrointestinal effects (e.g., nausea analogs in models), increased heart rate, elevated liver enzymes, pancreatitis signals, hypoglycemia risk (especially in glucose-modulating contexts), and other metabolic/organ impacts.

– Handling Precautions: Use personal protective equipment (gloves, eye protection); avoid inhalation, skin contact, or ingestion. Keep out of reach of unauthorized personnel.

– Storage: Sealed, away from light/moisture; refrigerate or freeze lyophilized form. Discard if compromised.

– Legal/Regulatory: Compliance with all local, state, and federal regulations required for research peptides. Not a dietary supplement. Consult qualified professionals for any experimental protocol.